Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRACR2A | Q9BSW2 | 11/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | ORAI1 | Q96D31 | 4/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KHK | P50053 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16827673 | 0.86 | PTGS1 (0.51) | CRACR2APTGS1ORAI1PLATTSHR | |
| SCHEMBL13135668 | 0.83 | CRACR2A (0.52) | CRACR2APTGS1ORAI1DPP4KDM4E | |
| SCHEMBL16845859 | 0.79 | SMYD3 (0.49) | ALDH1A1HPGDKHK | |
| SCHEMBL19308648 | 0.78 | DPP4 (0.54) | CRACR2AORAI1DPP4KDM4EALDH1A1 | |
| SCHEMBL1880912 | 0.76 | CRACR2A (0.56) | CRACR2APTGS1ORAI1KDM4EALDH1A1 | |
| SCHEMBL626659 | 0.76 | CRACR2A (0.56) | CRACR2APTGS1ORAI1KDM4EALDH1A1 | |
| SCHEMBL1667944 | 0.76 | CRACR2A (0.56) | CRACR2AORAI1KDM4EALDH1A1HPGD | |
| SCHEMBL30677204 | 0.76 | CRACR2A (0.53) | CRACR2AORAI1 | |
| SCHEMBL5214306 | 0.76 | PLAT (0.54) | PLATTSHR | |
| SCHEMBL1668441 | 0.75 | CRACR2A (0.65) | CRACR2AORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790725-B2 | Thiazolidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-08 | — | — | US | disclosed |
| CN-100341862-C | Thiazolidine derivative and medicinal use thereof | MITSUBISHI PHARMA CORP (JP) | 2007-10-10 | — | — | CN | disclosed |
| CN-1606549-A | Thiazolidine derivative and medical application thereof | MITSUBISHI PHARMA CORP (JP) | 2005-04-13 | — | — | CN | disclosed |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1426366-A1 | THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | CRACR2A 4739/4885PTGS1 1656/4885ORAI1 4207/4885 |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | DPP4, DPP7, DPP3 | CRACR2A 4778/4885PTGS1 795/4885ORAI1 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.